(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), a clinical-stage
biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary
technological platform DOS47, is pleased to announce the appointment of Mr. Hatem Kawar as the Company’s
Chief Financial Officer effective immediately. The appointment of Mr. Kawar is key in positioning HBP to
successfully transition the Company with efficiency and effectiveness.
- 0 Comments
- FY2022